Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.
about
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyBiomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease.Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathyAmiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Quantitating glomerular endothelial fenestration: an unbiased stereological approach.Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.Novel therapeutic targets for the treatment of Fabry disease.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Early markers of Fabry disease revealed by proteomics.Integrative Systems Biology Investigation of Fabry Disease.Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease.Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease.Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients.
P2860
Q28478586-1CC85784-E097-4BCA-9D5C-4B31D4998A14Q33323654-4849521D-5F3C-4F37-95C1-FB8FA011580AQ33703845-B22C0BD3-A0A9-4128-B1C3-BC04027370D4Q33737225-4CA97FEC-7C18-44E9-8B40-B9DC57BE6DADQ35028532-6C6B2B87-42F4-447D-B145-2571604E30E3Q35063588-65C3E608-8A5F-4FBC-827E-A3F86984AAD6Q35768834-8E7EA8B8-D24D-4EA8-9EA6-EC19F5E7E398Q36822452-5AD83F68-6668-4B74-A20C-8D98559D14C8Q38844401-C8888FCA-968D-48FD-9F34-1E3520AF7FBEQ41457854-C292CFA3-B037-4086-8594-7528AE179FA4Q42110868-89E09E4B-37C9-49A9-87A4-B870031A5858Q47123134-32673E8E-0DF1-4F46-B519-29EDEDB27DADQ51062136-78C4A247-0B82-46E7-A03D-5C72F0F1A8A8Q54531507-EC08945F-0462-446E-A74B-0A9A91F7D5DAQ55222984-47749A63-B7B1-4DFF-A789-24A05372B72C
P2860
Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Proteomics of specific treatme ...... tify biological abnormalities.
@ast
Proteomics of specific treatme ...... tify biological abnormalities.
@en
type
label
Proteomics of specific treatme ...... tify biological abnormalities.
@ast
Proteomics of specific treatme ...... tify biological abnormalities.
@en
prefLabel
Proteomics of specific treatme ...... tify biological abnormalities.
@ast
Proteomics of specific treatme ...... tify biological abnormalities.
@en
P2093
P2860
P356
P1476
Proteomics of specific treatme ...... ntify biological abnormalities
@en
P2093
Chevalia Robinson
David F Moore
Ehud Goldin
John A Wilkins
Oleg V Krokhin
Raphael Schiffmann
Ronald C Beavis
Roscoe O Brady
P2860
P304
P356
10.1073/PNAS.0611315104
P407
P50
P577
2007-02-14T00:00:00Z